Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Gilead Sciences (GILD) reported $6.67 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.3%. EPS of $1.81 for the same period compares to -$1.32 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $6.84 billion, representing a surprise of -2.46%. The company delivered an EPS surprise of -0.55%, with the consensus EPS estimate being $1.82.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Oncology- Cell Therapy- Tecartus- U.S. $40 million versus $56.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -27.3% change. Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $166 million compared to the $238.12 million average estimate based on three analysts. The reported number represents a change of -33.1% year over year. Product Sales- Other- Other- U.S. $47 million compared to the $40.07 million average estimate based on three analysts. The reported number represents a change of -20.3% year over year. Product Sales- HIV- Genvoya- U.S. $305 million compared to the $299.29 million average estimate based on three analysts. The reported number represents a change of -8.1% year over year. Total product sales- Total: $6.61 billion versus $6.75 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change. Revenues- Royalty contract and other revenues: $54 million compared to the $40.04 million average estimate based on six analysts. The reported number represents a change of +38.5% year over year. Product Sales- HIV- Genvoya- Total: $364 million versus the five-analyst average estimate of $375.96 million. The reported number represents a year-over-year change of -9.7%. Product Sales- HIV- Odefsey- Total: $281 million versus the five-analyst average estimate of $294.72 million. The reported number represents a year-over-year change of -9.4%. Product Sales- Total HIV- Total: $4.59 billion versus $4.56 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change. Product Sales- Veklury- Total: $302 million compared to the $387.03 million average estimate based on five analysts. The reported number represents a change of -45.6% year over year. Product Sales- Oncology- Cell Therapy- Tecartus- Total: $78 million versus $103.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -22% change. Product Sales- Oncology- Trodelvy- Total: $293 million compared to the $354.39 million average estimate based on five analysts. The reported number represents a change of -5.2% year over year. View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned -2.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks